

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



上海復星醫藥（集團）股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

## **TRADING HALT**

At the request of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”), trading in the shares (stock code: 02196) of the Company on The Stock Exchange of Hong Kong Limited will be halted with effect from 9:00 a.m. on Friday, 11 December 2015 pending the release of an announcement containing inside information.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Chen Qiyu**

*Chairman*

Shanghai, the People's Republic of China

11 December 2015

*As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changsheng Ma; and the independent non-executive Directors are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.*

\* *for identification purposes only*